sr-31747 and Shock--Septic

sr-31747 has been researched along with Shock--Septic* in 3 studies

Other Studies

3 other study(ies) available for sr-31747 and Shock--Septic

ArticleYear
A sigma ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice.
    Immunology, 1996, Volume: 88, Issue:3

    Sigma receptors originally described in distinct regions of the central nervous system are expressed on cells of the immune system. A sigma ligand, SR 31747A, was observed here to inhibit in vitro the Staphylococcal enterotoxin B (SEB)-driven lymphocyte proliferation. In mice, the drug confers a potent protection against the lethality induced by SEB, stimulates the SEB-induced serum release of interleukin (IL)-10 and inhibits at the same time the systemic release of IL-2, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6 and tumour necrosis factor-alpha (TNF-alpha). The enhancement of IL-10 production by this compound is also effective in nude mice treated with SEB, indicating that IL-10 of T-cell origin is not involved in this process. The finding that a sigma ligand protects against the SEB-induced toxicity provides insights into the clinical use of this family of compounds, particularly in food poisoning and septic shock where Staphylococcal enterotoxins are involved. The observation that this compound stimulates IL-10 synthesis indicates that it could be a potent regulatory agent of chronic inflammatory diseases.

    Topics: Animals; Cell Culture Techniques; Cell Division; Cyclohexanes; Cytokines; Enterotoxins; Female; Interleukin-10; Lymphocytes; Mice; Mice, Inbred BALB C; Shock, Septic; Staphylococcus aureus; T-Lymphocytes

1996
Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand.
    European journal of immunology, 1995, Volume: 25, Issue:10

    SR 31747A is a new sigma ligand eliciting immunosuppressive and anti-inflammatory properties. Here, we show that SR 31747A greatly enhances lipopolysaccharide (LPS)-induced systemic release of interleukin (IL)-10, while it inhibits the secretion of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma. In line with this finding, we also show by using quantitative reverse transcription-polymerase chain reaction analysis that SR 31747A increased LPS-induced IL-10 mRNA accumulation in spleen cells, whereas the level of both TNF-alpha and IFN-gamma mRNA was dramatically decreased. The enhancement of IL-10 production by SR 31747A treatment was also apparent in nude and severe-combined immunodeficient mice treated with LPS, clearly indicating that T and B cells were not involved. Finally, SR 31747A conferred protection against the lethal effect of LPS. The finding that SR 31747A strongly stimulates the synthesis of the natural anti-inflammatory cytokine IL-10, a property not observed with dexamethasone, provides new insights for the clinical use of this original compound, particularly in chronic inflammatory diseases where IL-10 is believed to be a pivotal regulatory component.

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Base Sequence; Cyclohexanes; Cyclosporine; Dexamethasone; DNA, Complementary; Female; Galactosamine; Immunosuppressive Agents; Interferon-gamma; Interleukin-10; Lipopolysaccharides; Lymphocyte Subsets; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Molecular Sequence Data; Polymerase Chain Reaction; Receptors, sigma; RNA, Messenger; Shock, Septic; Tumor Necrosis Factor-alpha

1995
In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747.
    The Journal of pharmacology and experimental therapeutics, 1995, Volume: 272, Issue:1

    In previous studies, the authors demonstrated that the new sigma ligand, cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexyl-phenyl) propen-2-ylamine hydrochloride (SR 31747), elicited a suppressive effect on immune responses through the sigma receptor expressed on lymphocytes. Here the effect of SR 31747 on the proinflammatory cytokine production by endotoxin-activated macrophages is examined. In vivo, SR 31747 dramatically blocked lipopolysaccharide-induced production of interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha in a dose-dependent manner (ED50, 2 mg/kg). Whereas SR 31747 suppression was not observed in vitro on lipopolysaccharide-induced IL-6 by macrophages, sera from SR 31747-treated animals displayed a strong inhibitory activity. It was shown that this effect could be completely reversed by the steroid receptor antagonist, mifepristone, which suggests that SR 31747 probably abrogated monokine production through an indirect mechanism that involves endogenous corticosteroids. This conclusion was supported by in vivo experiments that showed that 1) ablation of corticosteroids by use of mifepristone or adrenalectomy suppressed the effect of SR 31747 and 2) administration of SR 31747 induced an enhancement of the corticosterone level. It was also shown that this molecule improved the survival of animals with endotoxinic shock as a result of monokine inhibition. The combination of immunosuppression, previously described, along with anti-inflammatory properties makes SR 31747 a novel attractive molecule for therapeutic applications such as autoimmune diseases in which both immune and inflammatory disorders are involved.

    Topics: Adrenalectomy; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclohexanes; Endotoxins; Female; Interleukin-1; Interleukin-6; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred BALB C; Mifepristone; Rats; Rats, Sprague-Dawley; Receptors, sigma; Shock, Septic; Tumor Necrosis Factor-alpha

1995